Pramipexole
Also known as: Mirapex, Mirapex ER, Sifrol, Pexola, Prami
Lower numbers = closer to natural. Higher numbers = more enhanced.
Why this rating?
Pramipexole is an FDA-approved dopamine agonist for Parkinson's disease and restless leg syndrome. Per the FDA Mirapex label, it works via D2/D3 receptor agonism. Used off-label for prolactin control during 19-nor steroid cycles. It manages side effects, not enhances performance. Does not build muscle, burn fat, or improve athletic performance. Not WADA prohibited. Rated 1 (basically natty) because it is purely a side-effect/organ-support tool for prolactin control that does not move the muscular/physique/performance ceiling by any path, direct or indirect.
Overview
A non-ergot dopamine agonist with high D3 selectivity (7-10x over D2). Used off-label for prolactin control during 19-nor steroid cycles. Key advantage over cabergoline: NO cardiac valve fibrosis risk (no ergot derivation). Key disadvantage: higher impulse control disorder risk (gambling, hypersexuality, compulsive behaviors) and requires daily dosing. Less potent than cabergoline for prolactin suppression but safer cardiac profile.
Important Warnings
- •HIGH RISK of impulse control disorders (~18% in Parkinson's patients per the DOMINION study): gambling, hypersexuality, compulsive shopping
- •Higher ICD risk than cabergoline due to D3 selectivity
- •Can cause sudden sleep attacks without warning - dangerous if driving
- •NEVER stop abruptly - taper to avoid withdrawal syndrome
- •Avoid with dopamine antagonists (antipsychotics, metoclopramide) - negates effect
- •Caution with renal impairment - half-life dramatically extended
- •Hallucinations possible, especially in elderly
- •Orthostatic hypotension can cause falls
- •Off-label use for prolactin control - not FDA-approved for this
- •Cimetidine increases pramipexole levels 50%
Purpose & Use Cases
Prolactin Control (19-nor Cycles)
Controls prolactin elevation from trenbolone/nandrolone. Prevents: gynecomastia, erectile dysfunction, anorgasmia, mood issues. A controlled human study found dose-dependent prolactin suppression at doses as low as 0.1-0.3mg (Schilling et al. 1992); the exact percentage reduction in AAS users on 19-nors has not been formally studied.
Sexual Function Support
Maintains libido during suppressive cycles. Reduces refractory period. May counteract "deca dick" from nandrolone. D3 effects in mesolimbic system improve sexual drive.
Cardiac-Safe Cabergoline Alternative
No ergot-related cardiac valve fibrosis risk (unlike cabergoline). Preferred for those with cardiac concerns or using multiple cardiotoxic compounds.
Mood Enhancement
D3 agonism may provide mild antidepressant/motivation effects. Can help with AAS-related mood disturbances.
Benefits
- NO cardiac valve fibrosis risk (non-ergot)
- Potent prolactin suppression via D2 agonism
- High D3 selectivity may improve mood/motivation
- Short half-life allows rapid dose adjustment
- Can stop quickly if side effects develop
- >90% oral bioavailability
- Not a controlled substance
- Not on WADA prohibited list
- Generic available - relatively affordable
Good to Know
Dopamine agonist for prolactin: the non-ergot option
Like cabergoline, pramipexole works by D2 agonism: dopamine tonically suppresses prolactin, so it treats the prolactin-driven sides of 19-nors (tren/deca "dick", prolactin gyno, low libido). It is NOT an estrogen tool, an AI/SERM handles estrogen gyno and water; pramipexole handles prolactin.
Prami vs caber: the real trade-off
Pramipexole is NON-ergot, so it carries NO 5-HT2B cardiac-valve fibrosis risk (cabergoline's main long-term concern). The catch: it is less potent for prolactin, must be dosed DAILY (short half-life vs caber's ~65-100+ hour half-life per FDA labeling), and has a notably HIGHER impulse-control-disorder rate (compulsive gambling, hypersexuality, shopping, binge eating) partly due to its D3 selectivity. Choose based on which risk profile matters more.
Start low, dose at bedtime, and taper off
Nausea, sedation/sleep attacks and orthostatic blood-pressure drops mean you start very low (0.125mg) at night and titrate slowly. Bodybuilding doses are far below Parkinson's doses (1.5-4.5mg/day). Never stop abruptly after prolonged use: dopamine-agonist withdrawal syndrome (anxiety, dysphoria, fatigue) is real.
Only for 19-nor cycles: no PCT value
It does nothing for the HPTA (LH/FSH/testosterone) and has no recovery benefit. Run it only while a prolactin-raising 19-nor (trenbolone/nandrolone) is active, confirm need and dose with prolactin bloodwork, then taper off once the compound clears.
Dosage Guidelines
| Experience Level | Dosage Range |
|---|---|
| Beginner | 0.125 – 0.125 mg/day |
| Intermediate | 0.125 – 0.25 mg/day |
| Advanced | 0.25 – 0.5 mg/day |
Bodybuilding/off-label doses (0.125-0.5mg/day, occasionally up to ~1mg/day for heavy 19-nor stacks per bodybuilding-community sources) sit near the FDA-labeled restless-legs-syndrome range (0.125-0.75mg/day) and are far below Parkinson's doses (0.375-4.5 mg/day, titrated over ~7 weeks per FDA labeling). This off-label prolactin-control protocol is community-derived (bodybuilding/harm-reduction sources), not a clinically studied indication. Start 0.125mg at bedtime when beginning 19-nor. Increase to 0.25-0.5mg only if symptoms appear. Get prolactin bloodwork at 4-6 weeks. Target mid-normal prolactin. Taper off rather than stopping abruptly.
Half-life is extended in renal impairment, since pramipexole is cleared primarily unchanged by the kidneys.
Side Effects
Nausea
common16-28% incidence per FDA labeling (RLS dosing to early-Parkinson's monotherapy dosing). Usually improves over 1-2 weeks.
Take with food initially. Start low and titrate slowly.
Impulse Control Disorders
common17.7% of pramipexole users developed an impulse control disorder vs 6.9% of Parkinson's patients not on any dopamine agonist (DOMINION study, n=3090, Arch Neurol 2010). Pathological gambling, hypersexuality, compulsive shopping, binge eating, punding. D3 selectivity may increase risk vs other dopamine agonists. This data is from Parkinson's-range doses (up to 4.5mg/day); risk at the much lower off-label bodybuilding doses (0.125-0.5mg/day) has not been separately quantified.
Monitor behavior closely. Discontinue immediately if compulsive behaviors develop. Higher risk than cabergoline.
Somnolence/Sleep Attacks
common15-25% experience excessive sleepiness. Can cause sudden onset sleep without warning during activities.
Take at bedtime. Avoid driving until response known. Avoid CNS depressants.
Dizziness/Orthostatic Hypotension
common20-30% incidence. Blood pressure drop on standing.
Rise slowly from sitting/lying. Stay hydrated. Usually improves with time.
Insomnia
common15-20% incidence, despite also causing somnolence in others.
Take earlier in evening if sleep disrupted.
Hallucinations
uncommonMore common in elderly or those with Parkinson's. Visual hallucinations most common.
Reduce dose or discontinue. Seek medical attention.
Dopamine Agonist Withdrawal Syndrome
uncommonAnxiety, panic, depression, dysphoria, irritability, fatigue when stopping abruptly.
Always taper gradually. Never stop abruptly after prolonged use.
General Mitigation Strategies
Impulse control disorders are the major concern - monitor for gambling, sexual compulsivity, shopping, binge eating. D3 selectivity may increase ICD risk vs cabergoline. Take at bedtime to minimize daytime sedation. Start very low (0.125mg) and titrate slowly. Taper when discontinuing - never stop abruptly. Avoid alcohol and CNS depressants.
Post Cycle Therapy (PCT)
Does not affect HPT axis (LH, FSH, testosterone). No PCT benefit. Used only for prolactin control. Discontinue when 19-nor compounds clear (with gradual taper).
How It Works
Full agonist at D2 and D3 dopamine receptors, with 7-10x selectivity for D3. D3 receptors concentrated in limbic areas affect mood and reward. On pituitary lactotrophs, D2 agonism inhibits prolactin release (dopamine tonically suppresses prolactin). Also mildly stimulates GH release acutely via hypothalamic effects. >90% bioavailability, minimal hepatic metabolism, primarily renal excretion unchanged.
Fundamentals
Reference on the practices relevant to Pramipexole: how they are done and where they go wrong. Not a recommendation to use it.
Common Stacks
- Pramipexole 0.125-0.25mg + Trenbolone - prolactin control
- Pramipexole 0.125-0.25mg + Nandrolone - prevents "deca dick"
- Take at bedtime to minimize daytime sedation
- Do NOT combine with Cabergoline (redundant, additive D2 effects)
- Avoid alcohol - additive CNS depression
- Monitor bloodwork: prolactin at 4-6 weeks
Legal Status
FDA-approved for Parkinson's disease and restless leg syndrome. Not a controlled substance. Not on the WADA Prohibited List.
Legal status varies by country and changes over time. This is a general summary, not legal advice.
WADA Status
Pramipexole is not listed on the WADA Prohibited List. It is an FDA-approved dopamine agonist used for Parkinson's disease and restless leg syndrome.
References
- DailyMed - Pramipexole (Mirapex) Prescribing Information (FDA label)
- StatPearls - Dopamine Agonists
- Impulse Control Disorders in Parkinson Disease - DOMINION study, 3090 patients (Arch Neurol 2010)
- Schilling et al. - Neuroendocrine and Side Effect Profile of Pramipexole in Humans (Clin Pharmacol Ther 1992)